Resumes
Resumes
Thomas Bumol Phones & Addresses
-
1555 28Th Ave W, Seattle, WA 98199 (858) 412-4287
-
Big Sky, MT
-
Miramar Beach, FL
-
La Jolla, CA
-
6916 Eagle Dr, Nineveh, IN 46164
-
San Diego, CA
-
Indianapolis, IN
Business Records
Name / Title
Company / Classification
Phones & Addresses
President
Applied Molecular Evolution
Surgeons · Commercial Physical Research · Research & Development in Biotechnology · Biotechnology Products & Servi
Surgeons · Commercial Physical Research · Research & Development in Biotechnology · Biotechnology Products & Servi
3520 Dunhill St, San Diego, CA 92121
(858) 597-4990, (858) 597-4950
(858) 597-4990, (858) 597-4950
President
APPLIED MOLECULAR EVOLUTION, INC
Commercial Physical Research
Commercial Physical Research
10300 Campus Pt Dr SUITE 200, San Diego, CA 92121
(858) 597-4990
(858) 597-4990
Publications
Us Patents
Recombinant And Chimeric Ks1/4 Antibodies Directed Against A Human Adenocarcinoma Antigen
View pageUS Patent:
49753690, Dec 4, 1990
Filed:
Apr 21, 1988
Appl. No.:
7/184522
Inventors:
Lisa S. Beavers - Trafalgar IN
Thomas F. Bumol - Carmel IN
Robert A. Gadski - Indianapolis IN
Barbara J. Weigel - Indianapolis IN
Thomas F. Bumol - Carmel IN
Robert A. Gadski - Indianapolis IN
Barbara J. Weigel - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C12N 510
C12N 100
C12N 1500
C12N 100
C12N 1500
US Classification:
435 691
Abstract:
The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.
Chimeric Antibodies Directed Against A Human Glycoprotein Antigen
View pageUS Patent:
55807747, Dec 3, 1996
Filed:
Jul 31, 1989
Appl. No.:
7/387665
Inventors:
Lisa S. Beavers - Trafalgar IN
Thomas F. Bumol - Carmel IN
Robert A. Gadski - Indianapolis IN
Thomas F. Bumol - Carmel IN
Robert A. Gadski - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C12N 506
C12N 1513
C12N 1585
C12N 1513
C12N 1585
US Classification:
4352402
Abstract:
The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.